We have built a strong pipeline based on our breakthrough in situ transdifferentiation technology. Two platforms of approach, gene therapy and small molecule therapy, both aim to treat neurodegenerative diseases or neural injuries. Our programs include stroke, ALS, Huntington’s disease, Alzheimer’s disease, Spinal cord injury, Traumatic brain injury, and Parkinson’s disease.